MOTS-c FDA Status: Obesity and Osteoporosis, Not Endurance

Current status: MOTS-c is not FDA-approved, is not on the 503A bulk drug substances list, and no US pharmacy may legally compound it today. On July 23, 2026 an FDA advisory committee recommended adding it — by the narrowest margin of the entire meeting, and for an indication that has nothing to do with athletic performance.

The vote

At the July 23–24, 2026 Pharmacy Compounding Advisory Committee (PCAC) meeting, MOTS-c free base and MOTS-c acetate were voted on separately for the section 503A bulks list. Both cleared 7–5 in favor with two abstentions — the weakest favorable result of the four substances heard on day one¹².

That detail is worth a beat. Of the eight members appointed to the committee shortly before the meeting, seven voted yes on MOTS-c and one abstained; five members voted no and two abstained in total². The one new appointee who did not vote yes is the difference between MOTS-c's margin and the 8–6–1 that BPC-157, KPV and TB-500 received.

FDA has not published minutes, so all tallies here come from trade and news coverage of the meeting.

The indication FDA actually reviewed: obesity and osteoporosis

FDA published, in advance, the exact use it evaluated for each substance. For MOTS-c free base and acetate, it was obesity and osteoporosis³.

That is a metabolic and skeletal indication, and it is not remotely what MOTS-c is sold for in the athletic market. MOTS-c is marketed as a mitochondrial-derived peptide for endurance, VO2 max, exercise capacity, metabolic flexibility and "cellular energy." None of that was evaluated. The committee did not vote on endurance, performance, training adaptation, or recovery, for MOTS-c or for any other substance on the agenda.

The irony is that MOTS-c's most-cited research is exercise research — it was identified as an exercise-induced regulator of physical decline and muscle homeostasis in mouse work⁴, and the obesity and insulin-resistance findings that FDA reviewed come from the same original line of investigation⁵. FDA chose the metabolic indication, not the athletic one, presumably because that is where the nomination and the data pointed. We work through what the exercise literature does and does not support in MOTS-c for endurance: the evidence.

FDA's reviewers said no

The agency's scientists recommended against all seven peptides on the agenda, describing an absence of reliable human data and — repeatedly — an inability to define the substances chemically well enough to write quality standards for them⁶. For a mitochondrial-derived peptide sold in wildly varying preparations, that characterization concern is not academic.

The committee voted the other way. As NPR summarized it, the panel's endorsement "was a striking rejection of the FDA's stance"⁶.

What still has to happen

A favorable PCAC vote lists nothing. To add MOTS-c to 21 CFR 216.23, FDA must publish a proposed rule, take public comment, and issue a final rule⁷. The list today holds six substances, none of them peptides⁷.

The one completed 503A bulks rulemaking ran roughly three years — proposed rule December 2016, final rule effective March 21, 2019⁸. No FDA timeline exists for this round; the "9 to 18 months" number circulating online comes from vendor blogs, not from the agency.

What you should not conclude

• •Not that MOTS-c is FDA approved or endorsed for anything. 21 CFR 216.23(d) makes it misbranding to represent a compounded drug made with a listed bulk substance as "FDA approved, or otherwise endorsed by FDA generally or for a particular indication"⁷ — and that binds even after a substance completes rulemaking.
• •Not that the FDA blessed MOTS-c for endurance or fat loss. It evaluated obesity and osteoporosis. A clinician could later prescribe a listed substance for other uses at their own discretion, but that is a prescriber's judgment, not an agency finding about VO2 max.
• •Not that "obesity" here means a weight-loss product. The evaluation is of a bulk substance for compounding under a prescription, not a consumer fat-loss product. For where MOTS-c actually sits among fat-loss peptides, see peptides for fat loss and the head-to-head in 5-Amino-1MQ vs MOTS-c.
• •Not that anything changed for tested athletes. MOTS-c has no marketing authorization for human therapeutic use anywhere, which places it in WADA's S0 class of non-approved substances, prohibited at all times. See the WADA 2026 prohibited list for peptides and do peptides show up on drug tests?.

Where MOTS-c sits on FDA's lists today

MOTS-c is not in FDA's live Category 2 table. It appears in the second table on that page — substances "previously in category 2 of the interim policies" that "were withdrawn by the nominators"⁹. That is a procedural status, not a safety clearance, and it does not make MOTS-c compoundable.

The bottom line

MOTS-c received the narrowest favorable vote of the meeting, 7–5 with two abstentions, for obesity and osteoporosis — an indication no one buying MOTS-c for training is thinking about. FDA's own reviewers opposed it. Nothing is listed, nothing is approved, and no endurance or performance claim was examined by anyone in that room.

For the whole meeting, see what actually happened at the FDA peptide advisory vote. For the legal picture, are peptides legal?. For the science, our MOTS-c evidence review.